| Status: Assessment pending - company submission requested | |
Treatment of Wilson’s disease in patients intolerant to D-penicillamine therapy, in adults, adolescents and children aged 5 years or older. The AWMSG Scrutiny Panel considered trientine dihydrochloride suitable for a limited assessment at their meeting on 04/06/2026. |
|
Medicine details |
|
| Medicine name | trientine dihydrochloride (Cufence®) |
| Formulation | 100 mg and 200 mg hard capsules for oral administration |
| Reference number | 4279 |
| Indication | As above |
| Company | Univar Solutions BV |
| BNF chapter | Nutrition & blood |
| Assessment type | Limited |
| Status | Assessment pending - company submission requested |
| Scrutiny Panel meeting date | 04/06/2026 |